Letters by company
QXO, Inc.
10 letters discussing QXO. Everything written about it on this site is on its ticker page.
- Patient Capital Management 3Q26 Portfolio Activity & Attribution Opportunity Equity added Broadcom and rolled Meta call options into longer-dated contracts, while selling Illumina, JD.com and Genius Sports to fund higher-conviction ideas. The strategy argues that discounted Adobe and payments businesses retain durable cash generation, and that Precigen, QXO, Norwegian Cruise Line and UnitedHealth have identifiable paths to value creation despite near-term concerns. 3Q26 ADBE $98BADYEN $34BAVGO $1.6T
- Mar Vista Investment Partners U.S. Quality Premier Portfolio Commentary U.S. Quality Premier initiated ASML, exited Intuit and Ametek, added to Broadcom and GE Vernova, and trimmed several large holdings. The strategy argues that AI beneficiaries must convert infrastructure spending into earnings, while favoring GE Aerospace’s aftermarket cycle, Alphabet’s AI-led growth, TSM’s advanced-chip leadership, and QXO’s TopBuild acquisition. second quarter 2026 ASML $631BGOOGL $4.3TINTU $88B
- Fred Alger Management, LLC Alger Mid Cap Growth Fund Commentary Alger Mid Cap Growth Fund favored AI-infrastructure beneficiaries Astera Labs, Nebius Group and Comfort Systems USA, citing hyperscaler demand for connectivity, cloud capacity and data-center construction. GFL Environmental, Celsius Holdings and QXO detracted as acquisition financing, margin concerns and softer building-products markets weighed on sentiment. 2nd Quarter 2026 ALAB $52BCELH $7.1BFIX $52B
- Mar Vista Investment Partners U.S. Quality Portfolio Commentary Mar Vista initiated ASML and StandardAero, exited Intuit, added to Netflix, and trimmed several large technology and industrial holdings. It argues that aerospace aftermarket demand, semiconductor manufacturing bottlenecks, and commercially productive AI investment favor businesses with durable advantages and disciplined capital allocation. second quarter of 2026 APH $212BASML $631BINTU $88B
- Patient Capital Management 2Q26 Portfolio Activity & Attribution Opportunity Equity added Adyen, Global Payments, Genius Sports, Fidelity Wise Origin Bitcoin Fund and QXO preferred securities while exiting IBIT, Noble and Dave & Buster's. The strategy argues that depressed expectations create value in health care, payments, biotech and selected software, while retaining conviction in QXO's building-products consolidation strategy. second quarter of 2026 ADBE $98BADYEN $34BBIIB $34B
- Patient Capital Management 3Q25 Portfolio Activity & Attribution Patient Opportunity Equity Strategy added to Delta Air Lines and Norwegian Cruise Line during travel-sector weakness, doubled UnitedHealth after its pullback, and converted Precigen preferreds into common stock after Papzimeos won FDA approval. The strategy argues that Alphabet and Alibaba remain undervalued despite improving fundamentals, while maintaining conviction in turnarounds at Dave & Buster's, QXO and Crocs. 3Q25 PGEN $2.7BBABA $276BCROX $6B
- Patient Capital Management 2Q25 Portfolio Activity and Attribution Patient Opportunity Equity Strategy added UnitedHealth, Noble, Tempus AI, Clear Secure and Costco puts, while exiting New Fortress Energy over deteriorating fundamentals and balance-sheet strain. It expects tighter offshore-rig supply to favor Noble, sees UnitedHealth as a durable platform after Medicare Advantage setbacks, and backs Tempus’s AI-enabled molecular-data business. 2Q25 BABA $276BCOIN $47BCOST $433B
- Patient Capital Management 3Q24 Portfolio Activity and Attribution Patient Opportunity Equity added QXO and Dave & Buster’s, funded in part by exits from JPMorgan and Everi following its acquisition. The portfolio argues that QXO’s acquisition-led building-products strategy, Kosmos’s approaching cash-flow inflection, and Seadrill’s tightening deepwater-rig market offer idiosyncratic upside beyond macro conditions. 3Q24 BABA $276BET $69BEXPE $36B
- Patient Capital Management 3Q25 Portfolio Recap Patient Opportunity Equity built Precigen through a preferred investment ahead of Papzimeos approval, then converted shares and trimmed the enlarged exposure while backing its HPV and CAR-T pipeline. It added aggressively to UnitedHealth amid insurance-cycle pressures, and redeployed toward Crocs, Mattel, IAC and Biogen as valuations rose. 3Q25 PGEN $2.7BUNH $367B
- Patient Capital Management Samantha's Quarterly Letter Opportunity Equity argues that tariff policy has raised recession risk, but negotiated trade deals could stabilize markets and preserve the secular bull case. The portfolio added back airline exposure after trimming it during strength, and favors Nvidia, Amazon, Alphabet and Meta alongside cyclical travel names priced for a downturn. 1Q25 NVDA $5.2TAMZN $2.7TDAL $51B
